Sick people, particularly those with serious conditions, greatly prefer the company of their friends and family to residence in a hospital or nursing home.

Pharmaceutical companies have invested hundreds of millions of dollars in new HIV/AIDS treatments not out of altruism but because they can make up those research costs in sales.

My family lived off the land and summer evening meals featured baked stuffed tomatoes, potato salad, corn on the cob, fresh shelled peas and homemade ice cream with strawberries from our garden. With no air conditioning in those days, the cool porch was the center of our universe after the scorching days.

Every spring, this country will be reminded of the Lady from Texas. As trees bloom and flowers carpet our nation's capital, Lady Bird Johnson will be remembered. Only Lady Bird Johnson could, with her vision of a beautiful America, lay claim to spring as her memorial.

Getting a traditional pharmaceutical to the market can cost a billion dollars or more. Newer, more tailored and targeted drugs called biologics are even more complex and expensive. Simple economics dictates that companies and venture funds will invest more in products that can generate a sufficient return.

Those of us who lived through the worst of the HIV/AIDS epidemic from the early 1980s through the mid-1990s have a very special spot in our heart for home-based health care.

The number of people with HIV receiving Medicare benefits has grown over time, reflecting growth in the size of the of the HIV positive population in the U.S. but also an increased lifespan for people with HIV due to antiretroviral medicines and other treatment advances.